Clinical trials: Tumor Immunity
Autoimmune or Autoinflammatory Diseases, HIV
Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People
Prospective, multicenter, non-comparative cohort study of immunocompromised people vaccinated against Covid-19 with the aim to know the humoral and cellular response to BNT162b2 vaccination against SARS-CoV-2 variants.
- Conditions
- Autoimmune or Autoinflammatory Diseases, HIV, Multiple Sclerosis, Solid Tumors or Cancers
- Trial name
- COVIVAC-ID (NCT04844489)
- Testing
- Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19
- Where
- France
- Volunteers
- 377 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Colorectal Cancer, Colorectal Neoplasms
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer
Background: T-cells are white blood cells that can find and kill germs and tumors. Cancer can keep T-cells from working. Researchers think a new drug called AMP-224 might help the T-cells in people with cancer.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma
- Trial name
- NCT02298946
- Testing
- AMP-224, Stereotactic Body Radiation Therapy(SBRT), Cyclophosphamide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix Cancer
Perspectives: To analyse if the change of specific immune response will correlate with clinical effect of advanced cervix cancer after radio-chemotherapy.
- Trial name
- NCT03559803
- Testing
- Cisplatin
- Where
- 2 sites in China
- Volunteers
- 58 people
- Sponsor
- Sichuan University
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute
Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation
The stud will evaluate whether infusions of CD45RA-depleted lymphocytes from the donor early post-transplant is a safe way to improve immunity to common infections in recipients of TCR-alpha/beta depleted hematopoietic stem cell…
- Conditions
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Immune Deficiency Disease, Bone Marrow Failure Syndromes
- Trial name
- 45RA_NEG_DLI (NCT02337595)
- Testing
- CD45RA-depleted peripheral blood mononuclear cells
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Breast Cancer Stage II, Breast Cancer Stage III
Stress and Immunity Breast Cancer Project
An investigative study of the effectiveness of the BioBehavioral Intervention on Stage II/III breast cancer patients. A total of 231 patients were split between an assessment-only control group and an experimental group receiving…
- Trial name
- NCT03578627
- Testing
- BioBehavioral Intervention
- Where
- United States
- Volunteers
- 231 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Uveal Melanoma
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) alone or in combination with Ipilimumab and Nivolumab for patients with…
- Trial name
- NCT07364474
- Testing
- Melphalan through Percutaneous Hepatic Perfusion, Melphalan through Percutaneous Hepatic Perfusion in combination with Ipilimumab and Nivolumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Triple Negative Breast Cancer, Metastatic Breast Cancer
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
This research study is studying immunotherapy as a possible treatment for metastatic Triple Negative Breast Cancer (TNBC) in participants who are HLA-A2+.
- Trial name
- NCT03362060
- Testing
- Pembrolizumab, PVX-410
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Melanoma
Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine
In this study, a melanoma vaccine (5 melanoma peptides) is given with either Montanide or dendritic cells as adjuvants. This randomized trial will establish the safety of both vaccines and compare the 2 vaccine adjuvants in their…
- Trial name
- NCT00124124
- Testing
- KLH; Peptides; Dendritic Cells, KLH, peptides plus Montanide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Dr. Nina Bhardwaj
Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.
- Conditions
- Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL), High-grade B-cell Lymphoma (HGBCL)
- Trial name
- NCT04745559
- Testing
- Pneumococcal conjugate vaccine (PCV13), CD19 targeted CAR T Cell Therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Hepatocellular Cancer, Hepatocellular Carcinoma
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Most people with advanced HCC survive an average of 6 to 9 months.
- Conditions
- Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT03937830
- Testing
- durvalumab, Doxorubicin-Eluting Beads, TACE
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers
This protocol will study the impact of cryoablation on immune response in patients diagnosed with invasive breast cancers smaller than 1.5 cm. It will profile the immune response to cryoablation of invasive breast cancers.
- Trial name
- NCT01856036
- Testing
- Cryoablation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Saint John's Cancer Institute
Immunity, Innate, Prostatic Neoplasm
Measurement of Natural Killer Cell Activity in Whole Blood in Men Being Screened for Prostate Cancer With Biopsy
This study will look at measuring the activity of natural killer (NK) cells using the in vitro diagnostic device NK Vue in subjects being screened for prostate cancer using prostate biopsy.
- Trial name
- ANKA-PCA (NCT03242265)
- Testing
- IVDD for NK cell activity in whole blood
- Where
- Canada
- Volunteers
- 84 people
- Sponsor
- ATGen Canada Inc
Metastasis of Malignant Neoplasm to Lymph Node
A Clinical Trial of Stereotactic Ablative Radiotherapy for Metastatic Lymphadenopathy
Lymph node metastasis is one of the most common sites to develop disease recurrence or progression after initial local treatment for primary solid malignancies or systemic treatment for advanced metastases.
- Trial name
- NCT02803151
- Testing
- Stereotactic ablative radiotherapy
- Where
- Taiwan
- Volunteers
- 59 people
- Sponsor
- National Taiwan University Hospital
Influenza
Optimizing Influenza Vaccination in Surgical Oncology Patients
Seasonal influenza (flu) is a significant and sometimes serious health issue in the U.S. The Centers for Disease Control (CDC) estimates that over 200,000 people are hospitalized in the U.S each year related to the flu.
- Trial name
- NCT01698177
- Testing
- Influenza vaccine
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- Stony Brook University
Rectal Cancer
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of CEA positive rectal cancer patients. 1.
- Trial name
- CEA+RC-BCG (NCT02403505)
- Testing
- CEA protein antigen plus BCG Vaccine Mix for percutaneous use
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Acute Myeloid Leukemia
Reduction of Cord Blood Transplantation Toxicity in Patients With Acute Myeloid Leukemia
Multicentric evaluation of the reduction of unrelated cord blood transplantation (UCBT) toxicity by using reduced intensity conditioning (RIC) in patients with acute myeloid leukaemia.UCBT related mortality and morbidity were…
- Trial name
- MINICORD (NCT00797758)
- Testing
- Cord blood transplantation
- Where
- France
- Volunteers
- 76 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hyper-Immunoglobulin E. Syndrome (HEIS), Chronic Granulomatous Disease (CGD)
Skin Immunity Sample Collection Involving Blisters and Biopsies
Background: The way the body heals and protects itself from getting sick is called the immune response. Some people with weak immune systems get sick often or get rashes and skin infections.
- Trial name
- NCT03921515
- Testing
- Blister induction, Skin Biopsies
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Uterine Cervical Neoplasms
Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer
BVAC-C is an immunotherapeutic vaccine using B-Cell and Monocytes as antigen-presenting cells. This study is consists of 2 parts. Phase I is for safety evaluation, and Phase IIa is for efficacy assessment.
- Trial name
- NCT02866006
- Testing
- BVAC-C, Topotecan
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Cellid Co., Ltd.
Sars-CoV-2 Infection
Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment
The Coronavirus Disease 2019 (COVID-19) pandemic has claimed over 5 million lives globally. Fortunately, a substantial and growing number of SARS-CoV-2 vaccines with very high efficacy have been developed, manufactured, and…
- Trial name
- NCT05119738
- Testing
- Three doses of BNT162b2 (observational), Two doses of Coronavac and one dose BNT162b2 (observational)
- Where
- Chile
- Volunteers
- 122 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Ovarian Serous Adenocarcinoma, Undifferentiated Carcinoma of Ovary
Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity
This study is a clinical study aiming at establishing immunological assays for the qualitative and quantitative evaluation of WT-1, Survivin and HPV16 E7-specific immune responses in cancer patients.
- Conditions
- Ovarian Serous Adenocarcinoma, Undifferentiated Carcinoma of Ovary, Cervical Cancer, Cervical Intraepithelial Neoplasia, Grade 3
- Trial name
- NCT02016833
- Testing
- Blood Sampling
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- PX Biosolutions